WSLCB – Board Caucus
(September 04, 2018)

Here are some observations from the September 4th WSLCB Board Caucus.

My top 3 takeaways:

  • The Board discussed challenges for medically compliant product rulemaking, one of their four priorities, by the end of the year (transcript, audio).
    • Member Russ Hauge cited former Policy and Rules Coordinator Joanna Eide’s departure as the major reason for this concern. Chair Jane Rushford concurred.
    • Hauge suggested convening a working group to help. Rushford put it on her agenda for a meeting scheduled with WSLCB Director Rick Garza the following day (September 6, 2018).
    • Rushford: “[I]t’s become quite a serious issue with our stakeholders and needs our attention.”
    • The Board will next take the issue up collectively at the next Board Caucus meeting (September 11, 2018).
  • The Board discussed adjusting the penalty matrix for traceability violations for what they consider aggravated situations (transcript, audio).
    • Hauge noted that the current penalties for non-aggravated situations are the same as those for situations like untagged products.
    • Rushford concurred: “It’s disproportionate the way that it, that that played out, given that we’ve had much less significant violations that have been, you know, have had the same penalty.”
  • The Board discussed investment and vetting of financiers given the emergence of investment money from publicly traded Canadian companies (transcript, audio).
    • Hauge: “On the one hand … we could take the position that okay, it’s a publicly-traded company that wants to make this investment, therefore we should vet every shareholder, and which … would effectively bar investment by publicly-traded companies or most people … or entities with sophisticated corporate identities … I don’t think we want to do that, or if we do, like we want to do that like Colorado, we should be explicit about it”
    • Hague: “On the other hand … my understanding is that Licensing doesn’t have a real clear template as to how far to go … there are issues about how far should we go to protect the public in vetting financiers that are corporate entities.”
    • Rushford agreed to take it up with Garza at the next Caucus meeting.

Here are shared documents for your review: